New strategies for active immunotherapy with genetically engineered tumor cells

Curr Opin Immunol. 1992 Oct;4(5):619-23. doi: 10.1016/0952-7915(92)90037-f.

Abstract

While previous tumor vaccine strategies have shown intriguing results, clearcut efficacy has been difficult to establish in human trials. Recently, newer approaches have been developed in animal systems that modify tumor cells genetically so that they express new antigens or secrete certain cytokines. Engineering tumor cells to secrete cytokines in a paracrine fashion can induce powerful local cytokine effects without producing significant systemic toxicity. In addition to local inflammation, this approach can alter the presentation of tumor antigen or activation of tumor antigen-specific T lymphocytes, resulting in systemic antitumor immunity.

Publication types

  • Review

MeSH terms

  • Genes, MHC Class II
  • Humans
  • Immunotherapy / methods*
  • Interferon-gamma / genetics
  • Interleukins / genetics
  • Mutagenesis
  • Neoplasms / therapy*
  • Transfection*
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Interleukins
  • Tumor Necrosis Factor-alpha
  • Interferon-gamma